title: Changes in the intraocular cytokine levels after intravitreal bevacizumab in uveitic macular edema.
abstract: OBJECTIVE
  To evaluate the changes in intraocular cytokine after intravitreal bevacizumab (IVB) for uveitic cystoid macular edema (CME).
  
  
  METHODS
  The authors evaluated 9 eyes of 8 patients who underwent IVB for uveitic CME. The aqueous humor-levels of vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β(2)were measured using suspension array technology at baseline and 1 month after IVB.
  
  
  RESULTS
  The VEGF level was decreased to insignificant level (p = .008). TGF-β(2) and TNF-α levels increased significantly (p = .008 and .021, respectively). IL-6 and IL-8 showed no significant change (p = .051 and.110, respectively).
  
  
  CONCLUSIONS
  IVB resulted in a significant decrease of VEGF levels, which was associated with anatomical improvement of CME at 1 month. Compensatory elevations of proinflammatory cytokines (IL-6 and IL-8) after selective VEGF inhibition were not observed. Marked elevation of TGF-β(2) after IVB seems to play an immunosuppressive role.
authors.affiliation: Department of Ophthalmology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seocho-Gu, Seoul, Korea.
authors.forename: Sohee
authors.initials: S
authors.lastname: Jeon
authors.forename: Won Ki
authors.initials: WK
authors.lastname: Lee
authors.forename: Younhea
authors.initials: Y
authors.lastname: Jung
mesh_terms: D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001082:Aqueous Humor / Q000737:chemistry / Q000187:drug effects; D000068258:Bevacizumab; D016207:Cytokines / Q000032:analysis / Q000378:metabolism*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014605:Uveitis / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D000068258:Bevacizumab